This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naluzotan
Accession Number
DB05562
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
PRX-00023
Categories
UNII
LQ54E5B4EW
CAS number
740873-06-7
Weight
Average: 450.64
Monoisotopic: 450.266462274
Chemical Formula
C23H38N4O3S
InChI Key
SPWZXWDPAWDKQE-UHFFFAOYSA-N
InChI
InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
IUPAC Name
N-(3-{4-[4-(cyclohexylmethanesulfonamido)butyl]piperazin-1-yl}phenyl)acetamide
SMILES
CC(=O)NC1=CC=CC(=C1)N1CCN(CCCCNS(=O)(=O)CC2CCCCC2)CC1

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders and depression.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 1A
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of adverse effects can be increased when Naluzotan is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Naluzotan is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Naluzotan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Naluzotan.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Naluzotan.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Naluzotan is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Naluzotan.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Naluzotan is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Naluzotan.
AcenocoumarolThe risk or severity of adverse effects can be increased when Naluzotan is combined with Acenocoumarol.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
9605731
BindingDB
50187377
ChEMBL
CHEMBL209821
Wikipedia
Naluzotan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentEpilepsies / Epilepsy, Localization Related / Temporal Lobe Epilepsy1
3CompletedTreatmentAnxiety Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0489 mg/mLALOGPS
logP2.68ALOGPS
logP2.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)11.08ChemAxon
pKa (Strongest Basic)7.64ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area81.75 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity127.77 m3·mol-1ChemAxon
Polarizability51.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr: Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi: 10.1097/JCP.0b013e31816774de. [PubMed:18344738]
  2. de Paulis T: Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression. Curr Opin Investig Drugs. 2007 Jan;8(1):78-86. [PubMed:17263189]
  3. Iyer GR, Reinhard JF Jr, Oshana S, Kauffman M, Donahue S: Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects. J Clin Pharmacol. 2007 Jul;47(7):817-24. doi: 10.1177/0091270007300953. Epub 2007 May 10. [PubMed:17495280]

Drug created on November 18, 2007 11:26 / Updated on November 02, 2018 06:11